Thirty Years of Monoclonal Antibodies and Protein A: A Retrospective

View PDF
Herman Waldmann's notebook

Photo 1: A page from Herman Waldmann’s notebook

In 1980 at the University of Cambridge’s department of pathology, I worked with Herman Waldmann to develop monoclonal antibodies (MAbs) as treatments for graft-versus-host disease (GVHD). That disease is associated with serious complications of stem cell transplantation when attacking T-cells can damage the lungs, liver, skin, and other organs. If we could find a specific MAb that would work with the human complement system to kill those cells, they could be selectively removed from the bone marrow. The human complement system enables the body to destroy cells targeted with antibodies.

Please log in to access this content.

Learn more:


1 Bolton GR, Mehta KK. The Role of More than 40 Years of Improvement in Protein A Chromatography in the Growth of the Therapeutic Antibody Industry. Biotechnol. Prog. 32(5) 2016: 1193-1202. •

Formerly a visiting professor of therapeutic immunology at the University of Oxford (Oxford, UK), Geoff Hale is Managing Director at BioArchitech Ltd. in Cambridge, UK.

Leave a Reply